NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one ...

Oblenio has begun dosing patients in its phase 1a first‑in‑human trial of LBL‑051, a tri‑specific T cell engager designed to ...

BeOne Medicines has been awarded an Innovation Passport for its investigational bispecific antibody BGB‑B2033, marking a significant step in the company’s plans to advance new treatment options for ...

Polpharma Biologics has announced that the FDA and EMA have accepted for review the BLA and MAA for PB016, a proposed ...

Qnovia has secured a worldwide exclusive licence to a new antimicrobial peptide developed at the University of Virginia, ...

CelLBxHealth has announced the publication of an independent, peer‑reviewed study demonstrating that its Parsortix platform ...

Johnson & Johnson has announced positive topline results from the phase 3 MonumenTAL‑6 study, which evaluated TECVAYLI and ...

Sanofi has received European Commission approval to extend the indication of MenQuadfi to infants from six weeks of age, broadening access to protection against invasive meningococcal disease caused ...

There are currently no approved pharmacological treatments for cALD in the EU.

Infinitopes has dosed the first patient with ITOP1, its lead investigational therapeutic cancer vaccine, marking the first ...

The CHMP has adopted a positive opinion recommending approval of Lynavoy for the treatment of cholestatic pruritus in adults ...

Atsena Therapeutics has received orphan designation from the European Medicines Agency for its two clinical‑stage gene ...